Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Short Maintenance Trial
2024-512975-11-01Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of avelumab in transitional cell carcinoma (TCC), bladder cancer and muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by Erasmus MC. Primary endpoint: 18-month overall survival. Planned start Jan 2025; status: authorised.
02
Drugs
avelumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2024-512975-11-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512975-11-01.